Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NYM096/177Lu-NYM096 in Metastatic Clear Cell Renal Cell Carcinoma
NCT06649682Phase 1Suspended
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-NYM096 in clear cell renal cell carcinoma (ccRCC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events (Phase A) at 1 week and Dose-Limiting Toxicity at 8 weeks. Started Nov 2024; status: suspended.
02
Drugs
177Lu-NYM096
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06649682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649682.